The association between antiglaucomatous agents and Alzheimer's disease.

ABSTRACT:

Objectives

To estimate the risk of Alzheimer's disease (AD) associated with long-term use of topical glaucoma medications among middle-aged and older glaucoma patients, and compare the AD risk among various glaucoma subtypes.

Methods

This nationwide population-based cohort study utilized insurance claims data from Taiwan's National Health Insurance Research Database between 2008 and 2019. Participants were adults aged 45 years or older either with a diagnosis of glaucoma or without. Those with glaucoma must have received single antiglaucomatous medication (including α2-adrenergic agonists, cholinergic agonists, beta-blockers, prostaglandin analogs, and pilocarpine) for over 90 days. Those with pre-existing AD diagnoses prior to the index date were excluded.

Results

A

SUBMITTER: Chou CC 

PROVIDER: S-EPMC11621119 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature